Best Aquila Edwards Podcasts (2025)

1
Episode 67. Management of CMV in Hematologic Malignancies 40:01

Play Pause

1M ago40:01

40:01

Join hosts Eddie, Ashwin, and Raj as they welcome Dr. Michelle Yong and Dr. Gemma Reynolds, academic infectious diseases physicians from the Peter MacCallum Cancer Centre and the National Centre for Infections in Cancer, for an in-depth discussion on cytomegalovirus (CMV) management in immunocompromised hematology patients. Key Topics Covered Funda…

1
Episode 66. International Myeloma Society 2025 Annual Meeting Updates with Dr. Alfred Garfall: The Bispecific Bonanza 52:16

2M ago52:16

52:16

This episode provides comprehensive coverage of key clinical trial updates from the 2025 International Myeloma Society (IMS) Annual Meeting in Toronto, with special focus on bispecific antibodies and novel immunotherapies across the multiple myeloma disease continuum—from smoldering disease through relapsed/refractory settings. Dr. Alfred Garfall p…

1
Episode 65. Circulating Tumor DNA in DLBCL with Dr. Ash Alizadeh and Dr. David Russler-Germain 53:08

3M ago53:08

53:08

In this episode of Blood Cancer Talks, hosts Eddie, Ashwin, and Raj welcome two distinguished experts to explore the cutting-edge field of circulating tumor DNA (ctDNA) in B-cell lymphomas. Dr. David Russler-Germain, a lymphoma clinician from Siteman Cancer Centre at Washington University in St. Louis, returns as a familiar voice to the podcast aud…

1
Episode 64. Lymphoma Updates from EHA and ICML 2025 with Dr. Adrian Minson 43:03

4M ago43:03

43:03

In this episode of Blood Cancer Talks, we have Dr. Adrian Minson from the Peter MacCallum Cancer Centre to discuss the latest developments in lymphoma presented at the recent EHA and ICML meetings in June 2025. The episode focuses primarily on the emerging role of bispecific antibodies in various combinations and treatment settings for diffuse larg…

1
Episode 63. Management of Follicular Lymphoma with Dr. Gilles Salles 51:37

5M ago51:37

51:37

In this episode, we discuss the management of follicular lymphoma with Dr. Gilles Salles from Memorial Sloan Kettering Cancer Center. Here are the articles we discussed: 1. Relevance of Bone Marrow Biopsy in Follicular Lymphoma: https://pubmed.ncbi.nlm.nih.gov/35787017/ 2. TROG 99.03 (RCT of Systemic Therapy after Involved-Field Radiotherapy in Pat…

1
Episode 62. Unpacking MIDAS Trial in Myeloma with Dr. Meera Mohan 25:05

6M ago25:05

25:05

In this episode, we dissect the phase 3 MIDAS trial in newly diagnosed transplant-eligible multiple myeloma with Dr. Meera Mohan. https://pubmed.ncbi.nlm.nih.gov/39841461/ https://pubmed.ncbi.nlm.nih.gov/40459097/By Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff

1
Episode 61. Menin Inhibitors in AML with Dr. Eytan Stein 56:24

6M ago56:24

56:24

In this episode, we took a deep dive intro the landscape of menin inhibitors in AML with Dr. Eytan Stein from MSKCC. Here are the key trials and studies we discussed: ELN 2022 AML Classification https://ashpublications.org/blood/article/140/12/1345/485817/Diagnosis-and-management-of-AML-in-adults-2022 Predictors of outcomes in adults with AML and K…

1
Episode 60. Emergency Podcast-AQUILA and STARGLO 54:33

7M ago54:33

54:33

In this episode, we discuss the recent proceedings at the FDA ODAC meeting on AQUILA trial in smoldering myeloma and STRAGLO in R/R DLBCL, and provide an update to our audience on some of the clinically relevant data presented from those trials, along with insights from the panelists. Here is the link to the webpage with FDA briefing documents and …

1
Episode 59. Management of Systemic Mastocytosis with Dr. Daniel DeAngelo 1:03:18

8M ago1:03:18

1:03:18

In this episode, we discussed the management of systemic mastocytosis with Dr. Daniel DeAngelo from the Dana Farber Cancer Institute. Here are the key studies we discussed: Midostaurin https://www.nejm.org/doi/10.1056/NEJMoa1513098?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200www.ncbi.nlm.nih.gov Avapritinib EXLPORER study: …

1
Episode 58: CAR Transgenic T-cell Lymphoproliferative Neoplasms (CTTLN) with Dr. Piers Blombery 50:24

9M ago50:24

50:24

In this episode, we explore the emerging entity of CAR Transgenic T-cell Lymphoproliferative Neoplasms (CTTLN), a rare but important complication of CAR T-cell therapy. Dr. Piers Blombery from Peter MacCallum Cancer Center joins us to dissect two cases from the CARTITUDE-4 trial where patients developed T-cell lymphomas expressing the chimeric anti…

1
Episode 57. ASH 2024 Update on Leukemia/Myeloid Neoplasms with Dr. Jayastu Senapati 55:24

9M ago55:24

55:24

In this episode, we delve into the key clinically relevant abstracts in leukemia and myeloid neoplasms with Dr. Jayastu Senapati from the MD Anderson Cancer Center. Here are the links to the abstracts we discussed: Older AML: Ven+HMA vs 7+3 Abstract 450: https://ash.confex.com/ash/2024/webprogram/Paper210320.html Abstract 971: https://ash.confex.co…

1
Episode 56. Management of Newly Diagnosed CML with Dr. Hagop Kantarjian 1:02:55

11M ago1:02:55

1:02:55

In this episode, we discuss the management of CML with Dr. Hagop Kantarjian from MD Anderson Cancer Center. Here are the key articles we discussed: 1. ASC4FIRST RCT: Asciminib in newly diagnosed CML. https://pubmed.ncbi.nlm.nih.gov/38820078/ 2. 5-year follow-up of ENESTnd RCT (nilotinib): https://pubmed.ncbi.nlm.nih.gov/26837842/ 3. 10-year follow-…

1
Episode 55. ASH 2024 Myeloma Updates with Dr. Rakesh Popat 38:26

12M ago38:26

38:26

In this episode, we dive into the hottest updates in myeloma and amyloidosis at ASH 2024 annual meeting with Dr. Rakesh Popat. Here are the abstracts we discussed: 1. AQUILA Trial in High-Risk SMM Overview of the AQUILA trial testing single-agent daratumumab for high-risk smoldering multiple myeloma (HR-SMM) versus active monitoring. Discussion on …

1
Episode 54. ASH 2024 Lymphoma and CLL Highlights with Dr. David Russler-Germain 58:18

1y ago58:18

58:18

In this episode, we discussed the top abstracts in lymphoma and CLL presented at the ASH 2024 annual meeting in San Diego with Dr. David A Russler-Germain from Washington University. Here are the key abstracts we discussed: 1. 3 RCTs in Mantle Cell Lymphoma: a) Update on TRIANGLE: https://ash.confex.com/ash/2024/webprogram/Paper200735.html b) ENRIC…

1
Episode 53. Belantamab Makes a Comeback with Dr. Hang Quach 44:41

1y ago44:41

44:41

In this episode, we discuss the comeback of belantamab mafadotin in multiple myeloma with Dr. Hang Quach, along with some other important abstracts presented at EHA/ASCO 2024. Here are the studies we discussed: 1. DREAMM-7 RCT: Belantamab-Vd vs Daratumumab-Vd in relapsed MM. https://pubmed.ncbi.nlm.nih.gov/38828933/ 2. DREAMM-8 RCT: Belantamab-Pd v…

1
Episode 52. Management of Hodgkin Lymphoma in Older Adults with Dr. Andrew Evens 42:28

1y ago42:28

42:28

In this episode, we dive into the management of older adults with Hodgkin Lymphoma with Dr. Andrew Evens. Here are the key articles we discussed: 1. Comparison of ABVD versus Stanford V in older Hodgkin Lymphoma patients: https://pmc.ncbi.nlm.nih.gov/articles/PMC3906856/ 2. Outcome of older adults ECHELON-1: https://pubmed.ncbi.nlm.nih.gov/34162178…

1
Episode 51. Venetoclax in AML with Dr. Andrew Wei 56:57

1y ago56:57

56:57

In this episode, we discuss the history of venetoclax in AML, along with key clinical trials that have shaped its current use in AML. Here are the trials discussed in this episode: 1. VIALE-A study: https://www.nejm.org/doi/full/10.1056/NEJMoa2012971 2. 10 day Decitabine plus venetoclax for ND AML https://www.thelancet.com/journals/lanhae/article/P…

1
Episode 50. Quadruplets in Newly Diagnosed Transplant-Ineligible Myeloma with Dr. Timothy Schmidt 41:39

1+ y ago41:39

41:39

In this episode, we discuss the management of newly diagnosed transplant in-eligible multiple myeloma with Dr. Timothy Schmidt, with a special focus on IMROZ and BENEFIT RCTs testing quadruplets in this space. Here are the key papers we discussed: 1. MAIA trial (Daratumumab-Lenalidomide-Dexamethasone [DRd] vs Rd in newly diagnosed transplant inelig…

1
Episode 49. Updates on Low-Risk MDS with Dr. Maximilian Stahl 43:23

1+ y ago43:23

43:23

In this episode, we discuss updates on low-risk MDS with Dr. Maximilian Stahl with a focus on imetelstat and luspatercept. Here are the trials we discussed: 1. IWG 2019 response criteria https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7042664/ 2. MEDALIST trial: Luspatercept https://www.nejm.org/doi/10.1056/NEJMoa1908892?url_ver=Z39.88-2003&rfr_id=ori…

1
Episode 48. Management of Polycythemia Vera with Dr. Aaron Gerds 57:09

1+ y ago57:09

57:09

In this episode, we discussed the diagnosis and management of polycythemia vera with Dr. Aaron T. Gerds. Here are the shownotes with the key studies discussed: 1. MIPS PV scoring system https://pubmed.ncbi.nlm.nih.gov/31945802/ 2. REVEAL study https://ashpublications.org/blood/article/143/16/1646/506717/Association-between-elevated-white-blood-cell…

1
Episode 47. ASCO/EHA 2024 Lymphoma Updates with Dr. Gloria Iacoboni 47:48

1+ y ago47:48

47:48

In this episode, we reviewed the hottest updates in lymphoma from ASCO and EHA 2024, held in Chicago and Madrid respectively, with Dr. Gloria Iacoboni, a haematologist from University Hospital Vall d'Hebron, in Barcelona, Spain. Here are the key abstracts we discussed: 1. STARGLO: Glofit-GEMOX vs R-GEMOX in relapsed/refractory DLBCL https://library…

1
Episode 46. Updates in Myeloma MRD with Dr. Ben Derman and Dr. Manni Mohyuddin 57:48

1+ y ago57:48

57:48

In this episode, we dive into updates in Minimal Residual Disease (MRD) in multiple myeloma, along with the FDA ODAC meeting in April 2024 to decide on MRD as a surrogate endpoint for accelerated approval. Our guests are Dr. Benjamin Derman and Dr. Manni Mohyuddin. Here are the key papers we discussed: 1. Recording of FDA ODAC meeting: https://www.…

1
Episode 45. Updates in Primary Myelofibrosis with Dr. Ayalew Tefferi 1:00:53

1+ y ago1:00:53

1:00:53

In this episode, we discuss updates in primary myelofibrosis with Dr. Ayalew Tefferi from the Mayo Clinic. The key studies and trials discussed are as follows: · GIPSS: Genetically inspired prognostic scoring system that is exclusively based on genetic markers. § https://www.nature.com/articles/s41375-018-0107-z · MIPSS70+ Version 2.0: Mutation and…

1
Episode 44. Maintenance Therapy in Multiple Myeloma with Dr. Hira Mian and Dr. Manni Mohyuddin 52:58

1+ y ago52:58

52:58

In this episode, we dive into the data on maintenance therapy in multiple myeloma with Dr. Hira Mian and Dr. Manni Mohyuddin. Here are the key studies we discussed: 1. Meta-analysis of individual patient-level data from CALGB, IFM, and Italian maintenance RCTs (lenalidomide vs placebo or observation): https://pubmed.ncbi.nlm.nih.gov/28742454/ 2. My…

1
Episode 43. Essential Thrombocythemia with Dr. Raajit Rampal 35:28

1+ y ago35:28

35:28

In this episode, we discuss the diagnosis and management of Essential Thrombocythemia with Dr. Raajit Rampal. Here are the shownotes: 1. IPSET (revised) system, risk categories are defined by the presence of a prior thrombosis, age, and JAK2 mutation status: · Very low risk: No prior thrombosis, age ≤60 years, JAK2-unmutated · Low risk: No prior th…

1
Episode 42. CAR T-cell Therapy in Early Relapsed Myeloma with Dr. Samer Al Hadidi 54:49

2y ago54:49

54:49

In this episode, we talked about overall survival data from CARTITUDE-4 and KarMMa-3 that was presented at FDA ODAC meeting with Dr. Samer Al Hadidi from University of Arkansas Myeloma Center. RCTs of BCMA CAR T-cell Therapy in Early Relapsed Multiple Myeloma: a) KarMMa-3 (ide-cel): https://pubmed.ncbi.nlm.nih.gov/36762851/ b) CARTITUDE-4 (cilta-ce…

1
Episode 41. Career Development as a Clinician-Investigator with Dr. Ayalew Tefferi 47:22

2y ago47:22

47:22

In this episode, we discuss mentorship and career development as a clinician-investigator with Dr. Ayalew Tefferi from the Mayo Clinic.By Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff

1
Episode 40. Management of Newly Diagnosed AL Amyloidosis with Dr. Angela Dispenzieri 52:34

2y ago52:34

52:34

In this episode we discuss the management of newly diagnosed AL amyloidosis with Dr. Angela Dispenzieri from the Mayo Clinic. Here are the key articles discussed: 1. Optimal use of tissue biopsy in AL amyloidosis: https://pubmed.ncbi.nlm.nih.gov/28271734/ 2. Mayo 2004 staging: https://pubmed.ncbi.nlm.nih.gov/15365071/ 3. Mayo 2012 staging: https://…

1
Episode 39. ASH 2023 Leukemia and Myeloid Neoplasm Recap with Dr. Anand Patel 55:14

2y ago55:14

55:14

In this episode, we discuss top abstracts in the myeloid space from the American Society of Hematology 2023 meeting with Dr. Anand Patel. Here are the abstracts that were discussed: 1. TRANSFORM-1: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, International Phase 3 Study of Navitoclax in Combination with Ruxolitinib Versus Ruxolitini…

1
Episode 38. GVHD Prophylaxis in Allo-Transplant with Dr. Shernan Holtan 52:10

2y ago52:10

52:10

In this episode, we talk about GVHD prophylaxis, including recent data on post-transplant cyclophosphamide and abatacept with Dr. Shernan Holtan from the University of Minnesota. Here are the key trials we discussed: 1. BMT CTN 1203 trial: Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate,…

1
Episode 37. ASH 2023 Myeloma Recap with Dr. Ben Derman 1:01:40

2y ago1:01:40

1:01:40

In this episode, we discuss the key abstracts in myeloma and related plasma cell disorders at ASH23 with Dr. Benjamin Derman. Here are the abstracts discussed in this episode: First, we will focus on a few abstracts in precursor states, MGUS. 1. New diagnostic criteria for light chain MGUS (IStopMM): https://ash.confex.com/ash/2023/webprogram/Paper…

1
Episode 36. ASH 2023 Lymphoma Recap with Dr. Toby Eyre 50:59

2y ago50:59

50:59

In this episode, we review the hottest updates in lymphoma from the American Society of Hematology 2023 meeting with Dr Toby Eyre, a consultant haematologist at the University of Oxford in the UK. Here are the abstracts that were discussed: Mantle Cell Lymphoma 1. BOVen trial-A Multicenter Phase 2 Trial of Zanubrutinib, Obinutuzumab, and Venetoclax…

1
Episode 35. Bispecific Antibodies in Lymphoma with Dr. Michael Dickinson 1:08:40

2y ago1:08:40

1:08:40

In this episode, we delve into the weeds of bispecific antibodies across lymphomas with Dr. Michael Dickinson from Peter MacCallum Cancer Center, Melbourne, Australia. Here are the key articles we discussed: 1. Glofitamab for Relapsed/Refractory DLBCL: https://pubmed.ncbi.nlm.nih.gov/36507690/ 2. Long-term follow-up data on blinatumomab in relapsed…

1
Episode 34. Management of FLT3 AML with Dr. Alexander Perl 1:08:19

2y ago1:08:19

1:08:19

In this episode, we dive into the management of newly diagnosed and relapsed FLT3-positive AML with Dr. Alexander Perl. Here are the shownotes: 1. Assessment of minimal residual disease in standard-risk AML https://www.nejm.org/doi/full/10.1056/nejmoa1507471 2. RATIFY study: Midostaurin plus chemotherapy for AML with a FLT3 mutation https://www.nej…

1
Episode 33. The art of caring for patients at the end of life with Dr. Azra Raza 59:15

2y ago59:15

59:15

In this episode, we discuss the art of caring for terminally ill patients with Dr. Azra Raza. We also discuss her book titled "The First Cell", where she recounts numerous poignant stories of her patients with terminal cancer, and teaches us how to find hope amidst despair. Link to the book: https://www.amazon.com/First-Cell-Human-Pursuing-Cancer/d…

1
Episode 32: t(11;14) Multiple Myeloma and Role of Venetoclax with Dr. Rafael Fonseca and Dr. Martin Kaiser 58:50

2y ago58:50

58:50

In this episode, we discuss the biology and management of t(11;14) multiple myeloma and the role of venetoclax with Dr. Rafael Fonseca and Dr. Martin Kaiser. Here are the shownotes: 1. Excellent tweetorial thread by Dr. Fonseca highlighting some of the historical studies that identified t(11;14) and its prognostic impact in myeloma: https://x.com/R…

1
Episode 31. Management of CNS Lymphoma 51:40

2y ago51:40

51:40

In this episode, we discuss the management of primary CNS lymphoma, secondary CNS lymphoma and CNS prophylaxis with Dr. Kate Cwynarski. Here are the shownotes: 1. ASH 2022 data on PET scan in CNS lymphoma - https://ashpublications.org/blood/article/140/Supplement%201/1334/492207/Is-It-Possible-to-Omit-Bone-Marrow-Biopsy-in?searchresult=1 2. Elizabe…

1
Episode 30. Management of High-Risk Myeloma 1:08:29

2+ y ago1:08:29

1:08:29

In this episode, we discuss with Dr. Martin Kaiser how to identify and manage newly diagnosed high-risk multiple myeloma in the current era of effective frontline therapies. Here are the key studies that we touched upon: 1. Phase II OPTIMUM (MUKnine) trial in ultra-high-risk myeloma and PCL: https://pubmed.ncbi.nlm.nih.gov/37315268/ 2. Meta-analysi…

1
Episode 29. Management of Peripheral T-Cell Lymphoma 56:13

2+ y ago56:13

56:13

In this episode, we discuss the diagnosis and management of peripheral T-cell lymphoma with Dr. Steven Horwitz, with a focus on the 3 most common types-Peripheral T-cell Lymphoma-NOS, Angioimmunoblastic T-cell Lymphoma (AITL), and Anaplastic Large Cell Lymphoma (ALCL). Here are the key papers we discussed: 1. “How I Treat Peripheral T-cell Lymphoma…

1
Episode 28. Management of CCUS 47:54

2+ y ago47:54

47:54

In this episode, we discuss the diagnosis and management/monitoring of Clonal Cytopenias of Unknown Significance (CCUS) with Dr. Uma Borate. We also discuss the emerging data on risk stratification and key trials in this space that are currently ongoing. Here are the shownotes: 1. CCUS and risk of transformation to myeloid neoplasms: https://www.sc…

1
Episode 27. Management of PNH 1:03:29

2+ y ago1:03:29

1:03:29

In this episode, we delve into the diagnosis and management of Paroxysmal Nocturnal Hemoglobinuria (PNH) with Dr. Robert Brodsky. Here are the shownotes for key papers we discussed in the episode: How I treat PNH: https://pubmed.ncbi.nlm.nih.gov/33512400/ Alternative donor BMT with posttransplant cyclophosphamide as initial therapy for acquired sev…

1
Episode 26. Management of Newly Diagnosed Hodgkin's Lymphoma 57:26

2+ y ago57:26

57:26

In this episode, we delve into the history of frontline treatment in young/fit patients with Hodgkin's lymphoma and recent developments in the past decade with Dr. Nancy Bartlett from Washington University. Link for our Blood Cancer Talks Survey: https://bit.ly/BCTS Here are the key trials we discussed: 1. RATHL Trial (PET-adapted treatment of Adva…

1
Episode 25. Managing Acute Toxicities of CAR T-cell Therapy 49:08

2+ y ago49:08

49:08

In this episode, we discuss the management of acute toxicities of CAR T-cell therapy, including CRS, ICANS, and HLH with Dr. Michael Jain from Moffitt Cancer Center. Here are some of the key articles we discussed: 1. “How I treat refractory CRS and ICANS after CAR T-cell therapy”. https://pubmed.ncbi.nlm.nih.gov/36989488/ 2. CAR-HEMATOTOX score: ht…

1
Episode 24. ASCO/EHA 2023 Special: Updates on CAR T-cell Therapy in Myeloma 47:30

2+ y ago47:30

47:30

In this episode, we discuss the latest updates on CAR T-cell therapy in multiple myeloma, including the studies presented at ASCO and EHA 2023. Here are the show notes: 1. For a primer on CAR T-cell therapy, listen to our episode aired on July 22nd 2022 with Dr. Surbhi Sidana: https://share.transistor.fm/s/efc4acf9 2. RCTs of BCMA CAR T-cell Therap…

1
Episode 23. Bispecific Antibodies in Myeloma 51:35

2+ y ago51:35

51:35

In this episode, we delve into the latest data on bispecific antibodies in multiple myeloma with Dr. Ajai Chari. Here are the key studies discussed: 1. Teclistamab (MajesTEC-1 trial): https://pubmed.ncbi.nlm.nih.gov/35661166/ 2. Correlative analysis from MajesTEC-1 trial: https://ashpublications.org/blood/article/140/Supplement%201/241/487619 3. Ta…

1
Episode 22. Management of Low-Risk MDS 1:03:46

2+ y ago1:03:46

1:03:46

In this episode, we take a deep dive into low-risk MDS management. We have the privilege of being joined by the esteemed Dr. Mikkael Sekeres. We also explore his invaluable insights gained from his time at FDA ODAC and his latest literary endeavor, "Drugs and the FDA". Here are the key studies discussed: 1. ASH choosing wisely: https://www.hematolo…

1
Episode 21. Newly Diagnosed Mantle Cell Lymphoma 46:05

2+ y ago46:05

46:05

In this episode, we delve into the management of newly diagnosed mantle cell lymphoma with Dr. Martin Dreyling. Here the shownotes: 2:11 How to diagnose mantle cell lymphoma (MCL)? 6:51 Clinical manifestations of mantle cell lymphoma 7:52 How to manage leukemic variant of MCL? 12:08 Is Watch-and-Wait reasonable in selected cases of nodal MCL with l…

1
Episode 20. Management of Myeloma in LMICs 57:25

2+ y ago57:25

57:25

In this episode, we discuss the management of multiple myeloma in LMICs with Dr. Andrés Gómez-De León from UANL, Monterrey, Mexico, and Dr. Aditya Jandial from PGIMER, Chandigarh, India. This episode was inspired by an article in Lancet Haematology titled “The Underrepresented Majority”, which highlighted the lack of access to some of the basic ant…

1
Episode 19. Management of Primary Myelofibrosis 59:16

2+ y ago59:16

59:16

In this episode, we discuss the diagnosis and management of primary myelofibrosis with Dr. Ayalew Tefferi at Mayo Clinic, Rochester, Minnesota. Here are the show notes, including key studies discussed in this episode: 1. Risk stratification of PMF: MIPSS70 Score: http://www.mipss70score.it https://ascopubs.org/doi/full/10.1200/JCO.2017.76.4886 Gene…

1
Episode 18. Management of Smoldering Multiple Myeloma 46:32

3y ago46:32

46:32

1. How I Approach Smoldering Myeloma (Vaxman and Gertz): https://ashpublications.org/blood/article/140/8/828/485274 2. Risk-Stratification Models in SMM: Mayo 2018 model: https://pubmed.ncbi.nlm.nih.gov/29895887/ PETHEMA (Spanish) model: https://pubmed.ncbi.nlm.nih.gov/17576818/ PANGEA model: https://pubmed.ncbi.nlm.nih.gov/36858677/ IMWG SMM model…